Viridien Posts Strong 2025 Results Amid Leadership Transition

GlobeNewswire Inc.GlobeNewswire Inc.
|||2 min read
Key Takeaway

Viridien reported strong 2025 results with 4% revenue growth and 21% EBITDA surge. Leadership transition sees Sophie Zurquiyah move to chair while Henning Berg becomes CEO.

Viridien Posts Strong 2025 Results Amid Leadership Transition

Viridien reported robust financial performance in 2025, with segment revenue climbing 4% to $1,165 million while adjusted EBITDA surged 21% to $551 million, reflecting operational momentum across its core business divisions. The Geoscience segment led growth at 10%, while Earth Data contributed a 6% increase, demonstrating the company's ability to capitalize on demand across its service offerings. Net income under IFRS standards climbed 40% year-over-year to $71 million, underscoring improved profitability despite a competitive market environment.

The company's balance sheet benefited from disciplined capital management, with net cash generation of $107 million exceeding prior guidance and net debt declining to $753 million. This performance reflects both operational efficiency and management's commitment to debt reduction, positioning the company favorably for future investments and shareholder returns. Looking ahead to 2026, Viridien has guided for $100 million in net cash flow generation, signaling continued focus on deleveraging and financial strength.

The results coincide with a strategic leadership transition, with Sophie Zurquiyah moving from Chief Executive Officer to Non-Executive Chair. Henning Berg will assume the Chief Executive Officer role, bringing fresh perspective to the company's strategic direction while maintaining operational continuity. The transition underscores the board's confidence in leadership depth and its vision for sustained performance in the coming year.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 26

Related Coverage

GlobeNewswire Inc.

Sika AG Shareholders Approve Board, Boost Dividend to CHF 3.70 Per Share

Sika AG shareholders approved CHF 3.70 dividend and board re-election at 2026 AGM, with company reporting CHF 11.20B sales and 33,700 employees globally.

SXYAY
GlobeNewswire Inc.

17EdTech Posts Narrower Loss Despite Revenue Decline as AI Product Gains Traction

17EdTech reports Q4 revenue growth of 6.4% YoY and significant margin expansion, though full-year revenues declined 44% due to business model shift. New AI product 'Yiqi Aixue' shows strong pre-sale demand.

YQ
The Motley Fool

Slide Insurance Posts $444M Profit on Strong Revenue Growth; Insider Trims Position

Slide Insurance reported $444M net income and $1.16B revenue, up 36% YoY. Director sold $1M in shares via pre-arranged plan while maintaining substantial stake.

SLDE
GlobeNewswire Inc.

IMUNON Sets March 31 Call to Detail 2025 Results, OVATION 3 Trial Progress

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

IMNN
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.

IVA
GlobeNewswire Inc.

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.

IVA